Not Yet Recruiting
MRG003 With Gemcitabine for Second-line Advanced PDAC
NCT07685470
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Second Line Treatment
- Locations
-
Not specified
Clinical trial condition
Second Line Treatment
Explore clinical trials studying Second Line Treatment. Study availability and eligibility vary by location and protocol.
5 public trials
0 recruiting studies
Second Line Treatment trial results
Not Yet Recruiting
Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment
NCT06662877
- Conditions
- Biliary Tract Cancer, Biliary Tract Diseases, Biliary Tract Neoplasms, +7 more
- Locations
-
- The First Affiliated Hospital of Sun Yat-sen University Guangzhou, Guangdong, China
Not Yet Recruiting
Exercise in Patients With Advanced Non-small Cell Lung Cancer
NCT06374160
- Conditions
- Advanced Lung Carcinoma, Bronchial Neoplasms, Carcinoma, Bronchogenic, +14 more
- Locations
-
- West German Cancer Center (Department of Palliative medicine and Department of Medical Oncology), University Hospital Essen Essen, North Rhine-Westphalia, Germany
Completed
Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function
NCT04522908
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- HELIOS Klinikum Bad Saarow Bad Saarow, Germany
- Universitätsklinikum Köln AöR Cologne, Germany
- BAG / Onkologische Gemeinschaftspraxis Dresden, Germany
- Ev. Kliniken Essen-Mitte, Klinik für Internistische Onkologie Essen, Germany
Active, Not Recruiting
A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma
NCT07138885
- Conditions
- Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +10 more
- Locations
-
- Sun Yat-sen University Cancer Center Guangzhou, Guangdong, China